BioMarin Pharmaceutical Inc. (BMRN) News

BioMarin Pharmaceutical Inc. (BMRN)

Today's Latest Price: $77.96 USD

0.92 (1.19%)

Updated Nov 24 4:00pm

Add BMRN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

Filter BMRN News Items

BMRN News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest BMRN News From Around the Web

Below are the latest news stories about Biomarin Pharmaceutical Inc that investors may wish to consider to help them evaluate BMRN as an investment opportunity.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against BioMarin Pharmaceutical Inc.; Encourages Investors with Losses in Excess of $100K to Contact Firm - BMRN

NEW YORK, Oct. 2, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020, inclusive (the…

PR Newswire | October 2, 2020

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of BioMarin Pharmaceuticals Inc. (BMRN) Investors

LOS ANGELES--(BUSINESS WIRE)---- $BMRN #classaction--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired BioMarin Pharmaceuticals Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) securities between February 28, 2020 and August 18, 2020 (the “Class Period”). BioMarin investors have until November 24, 2020 to file a lead plaintiff motion. If you are a shareholder who suffered a loss, click here to participate. On A

Business Wire | October 2, 2020

BMRN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies BioMarin Pharmaceutical Inc. Investors of Class Action and Lead Plaintiff Deadline: November 24, 2020

NEW YORK, Sept. 30, 2020 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. ("BioMarin" or "the Company") (NASDAQ: BMRN) and certain of its officers, on behalf of…

PR Newswire | September 30, 2020

BIOMARIN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioMarin Pharmaceutical Inc. - BMRN

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against BioMarin Pharmaceutical Inc. (NasdaqGS: BMRN), if they purchased the Company’s securities between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”). This action is pending in the United States Distric

Business Wire | September 30, 2020

Akero Continues Efruxifermin Trial, And Other News: The Good, Bad And Ugly Of Biopharma

Akero Therapeutics to continue with Mid stage Efruxifermin trial Akero Therapeutics Inc. (AKRO) reported that the company has received a written guidance from the FDA, allowing the company to pursue a novel combined Phase 2b/3 study design for pivotal efruxifermin ((EFX)) trials in NASH patients. The proposed trial design entails...

Avisol Capital Partners on Seeking Alpha | September 29, 2020

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages BioMarin Pharmaceutical (BMRN) Investors to Contact Its Attorneys, Securities Fraud Class Action Filed

SAN FRANCISCO, Sept. 28, 2020 /PRNewswire/ -- Hagens Berman urges BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) investors to contact the firm now. A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: Feb. 28, 2020 – Aug. 18, 2020 Lead…

PR Newswire | September 28, 2020

BMRN INVESTIGATION ALERT: Bernstein Liebhard is Investigating BioMarin Pharmaceuticals For Violations of the Securities Laws

NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of BioMarin Pharmaceutical ("BioMarin" or the "Company") (NASDAQ: BMRN) resulting from allegations that BioMarin might have issued misleading information to the investing public. If you purchased BioMarin securities, and/or would like to discuss your legal rights and options please visit BMRN Shareholder Investigation or con

Business Wire | September 28, 2020

BMRN LOSSES ALERT: Bernstein Liebhard is Investigating BioMarin Pharmaceuticals For Violations of the Securities Laws

NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of BioMarin Pharmaceutical ("BioMarin" or the "Company") (NASDAQ: BMRN) resulting from allegations that BioMarin might have issued misleading information to the investing public. If you purchased BioMarin securities, and/or would like to discuss your legal rights and options please visit BMRN Shareholder Investigation or con

Business Wire | September 27, 2020

BioMarin to Participate in Four Upcoming Virtual Investor Conferences

SAN RAFAEL, Calif., Sept. 15, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in four upcoming virtual conferences. An audio webcast of the presentations will be available live. You can access the webcast at:…

PR Newswire | September 15, 2020

Review period extended for BioMarin application in Europe for hemophilia A gene therapy

BioMarin Pharmaceutical ([[BMRN]] -0.3%) discloses that the European Medicines Agency ((EMA)) has requested complete 52-week data from the 134 participants in its ongoing Phase 3 clinical trial, BMN 270-301, evaluating gene therapy valoctocogene roxaparvovec in patients with severe hemophilia A.The last follow-up visit should happen in November which will enable...

Seeking Alpha | September 9, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6151 seconds.